Drug Trial Radar · NCT05605509
RP-6306 in Patients With Advanced Cancer
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
May 24, 2023
Primary completion
Nov 14, 2025
Study completion Feb 5, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Repare Therapeutics
- First posted
- Nov 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to answer the following questions: * Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? * If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.
Conditions
- Advanced Cancer
Interventions
RP-6306Drug
Dose and schedule will be assigned at enrolment
GemcitabineDrug
Dose and schedule will be assigned at enrolment
FOLFIRI ProtocolDrug
Irinotecan Leucovorin FU
TrastuzumabDrug
standard doses q3weekly
RP-3500Drug
Dose and schedule will be assigned at enrolment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate of RP-6306 in patients with selected cancers receiving standard agentTime frame: 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
BCCA - Kelowna
Kelowna, British Columbia, Canada
BCCA - Vancouver
Vancouver, British Columbia, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Health Sciences Centre Research Inc.
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.